ClinicalTrials.gg
Active, not recruitingNCT05489237Updated Oct 5, 2026

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

A Phase 1 interventional study of IDRX-42 in Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST) and Digestive System Disease, sponsored by IDRX, Inc., a wholly owned subsidiary of GSK, LLC. Active, not recruiting at 31 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Primary conditionGastrointestinal Stromal TumorsRegistry: Gastrointestinal NeoplasmsReclassifiedWhy we changed it
Registry
Gastrointestinal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Gastrointestinal Stromal Tumors
Why
  1. The study's listed conditions name Gastrointestinal Stromal Tumors, a narrower term within Gastrointestinal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by IDRX, Inc., a wholly owned subsidiary of GSK, LLC (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Updated Oct 5, 20263 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
276
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Gastrointestinal Stromal Tumors with a site in United States — 19 open to participants now, 29 under way, 5 of them phase 3. Gastrointestinal Stromal Tumors · United States.

Enrollment
15th of 116
276 · median 55
Started
2022
with 4 others
Phase 1
32 of 139
3 open now
Primary completion
2027-03
later than 7 of 28 live
Registered
119th of 139
by date

Among the 139 studies in Gastrointestinal Stromal Tumors with a site in United States, this one is the 15th largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2022, is one of 32 in phase 1, reaches primary completion later than 7 of the 28 other live ones, and was the 119th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

19 of the 139 studies in Gastrointestinal Stromal Tumors with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Gastrointestinal Stromal Tumors with a site in United States, or all of them as a file.
02

Study summary

This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.

Read the detailed description

This is a Phase 1/1b open-label, first-in-human FIH study of IDRX-42, an orally administered small molecule tyrosine kinase inhibitor. Eligible participants will have metastatic and/or surgically unresectable GIST. The study consists of 2 parts. Phase 1 comprises dose escalation to assess clinical and pharmacologic profile and safety/tolerability after failure of at least prior imatinib and support choice of the recommended phase 1b dose(s) and schedule(s) (RP1bDs)). Phase 1b expansion will enroll separate cohorts of participants defined by numbers of lines of prior GIST therapy at the selected RP1bD(s) to assess the preliminary antitumor effect of IDRX-42 and further characterize the safety profile of IDRX-42 at the RP1bD(s). In addition, a Concentration-QTc (C-QTc) substudy will be conducted in a subset of participants enrolled at selected sites in the study to characterize the effects of IDRX-42 on QTc and other ECG parameters in GIST patients.

03

Conditions studied

  • Gastrointestinal Neoplasms
  • Gastrointestinal Stromal Tumor (GIST)
  • Digestive System Disease
  • Gastrointestinal Diseases
  • Metastatic Cancer

Keywords

  • GIST
  • IDRX
  • IDRX-42
  • Strate
  • StrateGIST
  • StrateGIST 1
  • GSK6042981
04

In context

Gastrointestinal Stromal Tumors Reclassified

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

This study's enrollment of 276 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.

Browse Gastrointestinal Stromal Tumors studies →

Lead sponsor

This is the only study on the registry with IDRX, Inc., a wholly owned subsidiary of GSK, LLC as lead sponsor.

First submitted before IDRX, Inc. became part of GlaxoSmithKline.

Compared within Gastrointestinal Stromal Tumors, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastrointestinal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1

  1. Male or female participants ≥18 years of age
  2. or cytologically confirmed and/or surgically unresectable GIST
  3. Documented progression on imatinib (Phase 1)
  4. Documented pathogenic mutation in KIT OR any PDGFRA mutation other than exon 18 mutations, determined through local testing
  5. At least one by v1.1 for participants with GIST
  6. (ECOG) performance status of 0 or 1
  7. Resolution of any toxicities from prior treatment(s) to ≤ Grade 1 by v5.0 criteria, or have resolved to baseline, at the time of first dose of study drug.
  8. Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions.

Additional for Phase 1b Exploratory Cohorts

  1. For Cohort 1, progressed on imatinib only ( therapy) and refused or are ineligible for other standard of care (SOC) therapies.
  2. For Cohort 2, progressed on both imatinib and sunitinib (third line therapy) or progressed on imatinib, sunitinib, and an additional agent (i.e., regorafenib or ripretinib) (fourth line therapy) or progressed on imatinib, sunitinib, regorafenib, and ripretininb (fifth line or greater therapy)
  3. For Cohort 3 [US, UK, China, and Japan only], treatment naïve (first line therapy) and refused or are ineligible for other standard of care (SOC) therapies.
  4. For Cohort 4, met the same criteria as Cohort 2 (third line or greater) and have also had prior treatment with agents NB003 or THE-630 or a line of therapy of bezuclastinib plus sunitinib combination.

Exclusion criteria

Exclusion Criteria:

  1. Any prior exposure to the following agents NB003 or THE-630 or bezuclastinib plus sunitinib combination (except for participants treated in Cohort 4 of Phase 1b).
  2. GIST with no documented mutation in both KIT and PDGFRA genes.
  3. Primary brain or known untreated or active central nervous system .
  4. Has an active uncontrolled infection, including, but not limited to, the requirement for intravenous antibiotics.
  5. Has significant, uncontrolled, or active cardiovascular disease.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
276 participants (actual)

Study arms

  • Experimental
    Dose Escalation (Phase I)

    Participants should have advanced (metastatic and/or surgically unresectable) GIST, following failure of at least prior imatinib therapy due to progression of GIST.

    Drug: IDRX-42

  • Experimental
    (Phase 1b) Cohort 1 - Participants with GIST progression after first-line imatinib therapy

    Participants with advanced GIST who have had GIST progression after first-line imatinib only (second line therapy setting) and refused or are ineligible for other standard of care (SOC) therapies.

    Drug: IDRX-42

  • Experimental
    (Phase 1b): Cohort 2 - Participants with GIST progression after 2 or more lines of TKI therapy

    Participants with metastatic and/or surgically unresectable GIST following progression EITHER after sequential imatinib then sunitinib (third-line therapy setting) OR after imatinib, sunitinib, and then an additional TKI agent (i.e., regorafenib or ripretinib) (fourth-line therapy setting) OR after imatinib, sunitinib, regorafenib, and ripretinib (5th line or greater therapy).

    Drug: IDRX-42

  • Experimental
    (Phase 1b): Cohort 3 - Participants with GIST who are treatment naïve

    Participants with metastatic and/or surgically unresectable GIST who are treatment naïve (first line therapy) and refused or are ineligible for other standard of care (SOC) therapies.

    Drug: IDRX-42

  • Experimental
    (Phase 1b): Cohort 4

    Participants with GIST progression who meet the same criteria as Cohort 2 (third line or greater TKI therapy) and have had prior treatment with investigational agents NB003 or THE-630 or a line of therapy of bezuclastinib plus sunitinib combination.

    Drug: IDRX-42

Interventions

  • Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.

07

What researchers measure

Primary outcomes

  1. Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)

    Time frame: When participant completes 1 cycle (28 days) treatment with safety and tolerability assessment by investigators

  2. Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)

    Time frame: Approximately 18 months from first participant enrolled

  3. Phase 1 (Dose Escalation) - Determination of the MTD and/or RP1bD(s) of orally administered IDRX-42

    Time frame: Approximately 18 months from first participant enrolled

  4. Phase 1 (Dose Escalation) - C-QTc sub-study: QTcF - concentration response analysis

    Time frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

  5. Phase 1b-Number of participants with TEAEs and with laboratory test results

    Time frame: Approximately 18 months

  6. Phase 1b - Objective Response Rate (ORR) mRESIST v1.1

    Time frame: Approximately 18 months

  7. Phase 1b - C-QTcF sub-study: QTcF - concentration response analysis

    Time frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

Secondary outcomes

  1. Phase 1 (Dose Escalation)- Number of participants with non-DLT TEAEs and with laboratory test results

    Time frame: 6 months

  2. Phase 1 (Dose Escalation) - ORR per mRECIST v1.1

    Time frame: 6 months

  3. Phase 1 (Dose Escalation) - Cmax; Maximum Observed Concentration of IDRX-42

    Time frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

  4. Phase 1 (Dose Escalation) - Tmax; Time of First Occurrence of Maximum Plasma Concentration (Cmax) of IDRX-42

    Time frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

  5. Phase 1 (Dose Escalation) - AUC 0-24; Area Under the Concentration-time Curve from Time Zero to 24 hours for IDRX-42

    Time frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

  6. Phase 1 (Dose Escalation) - Duration of response (DOR) per mRECIST v1.1

    Time frame: 6 months

  7. Phase 1 (Dose Escalation) - Time to response (TTR) per mRECIST v1.1

    Time frame: 6 months

  8. Phase 1 (Dose Escalation) - Progression-free survival (PFS), per mRECIST v1.1

    Time frame: 6 months

  9. Phase 1 (Dose Escalation) - C-QTcF sub-study: QTcF, heart rate, PR, QRS interval at baseline, post baseline and change from baseline.

    Time frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

  10. Phase 1b- Duration of response (DOR) per mRECIST v1.1

    Time frame: 18 months

  11. Phase 1b - PFS per mRECIST v1.1

    Time frame: 18 months

  12. Phase 1b - Clinical benefit rate (CBR) per mRECIST v1.1

    Time frame: 18 months

  13. Phase 1b - TTR per mRECIST v1.1

    Time frame: 18 months

  14. Phase 1b - Cmax; Maximum Observed Concentration of IDRX-42

    Time frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

  15. Phase 1b - Tmax; Time of First Occurrence of Maximum Plasma Concentration (Cmax) of IDRX-42

    Time frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

  16. Phase 1b - AUC 0-24; Area Under the Concentration-time Curve from Time Zero to 24 hours for IDRX-42

    Time frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

  17. Phase 1b - Overall survival

    Time frame: 18 months

  18. Phase 1b C-QTc sub-study: QTcF, heart rate, PR, QRS interval at baseline, post baseline and change from baseline.

    Time frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

08

Study locations

31 sites
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Chicago, Illinois 60611, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    St Louis, Missouri 63129, United States
  • GSK Investigational Site
    New York, New York 10065-6007, United States
  • GSK Investigational Site
    Portland, Oregon 97239, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111-2434, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Beijing, 100142, China
  • GSK Investigational Site
    Guangzhou, China
  • GSK Investigational Site
    Wuhan, 430022, China
  • GSK Investigational Site
    Bordeaux, 33076, France
  • GSK Investigational Site
    Lyon, France
  • GSK Investigational Site
    Marseille, 13005, France
  • GSK Investigational Site
    Villejuif, 94805, France
  • GSK Investigational Site
    Essen, North Rhine-Westphalia 45122, Germany
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Milan, 20133, Italy
  • GSK Investigational Site
    Chiba, 277-8577, Japan
  • GSK Investigational Site
    Kanagawa, 247-8533, Japan
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
  • GSK Investigational Site
    Rotterdam, South Holland 3075 EA, Netherlands
  • GSK Investigational Site
    Amsterdam, 1066 CX, Netherlands
  • GSK Investigational Site
    Seongnam-si Gyeonggi-do, 463-707, South Korea
  • GSK Investigational Site
    Seoul, 120-752, South Korea
  • GSK Investigational Site
    Seoul, 5505, South Korea
  • GSK Investigational Site
    Seoul, 6351, South Korea
  • GSK Investigational Site
    Barcelona, Spain
  • GSK Investigational Site
    Leeds, West Yorkshire LS9 7TF, United Kingdom
  • GSK Investigational Site
    London, SW3 6JJ, United Kingdom
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Mar 2027, 55 months after the start.

Of 21 phase 1 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 77. This study's planned 55 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2022
First posted
Aug 5, 2022
StartActual
Aug 3, 2022
Primary completionEst.
Mar 10, 2027
CompletionEst.
Mar 26, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (1 Germany, 1 Netherlands, 1 United Kingdom)
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Rotterdam, Netherlands
  • GSK Investigational Site · Leeds, United Kingdom
Show 3 removed
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Rotterdam, Netherlands
  • GSK Investigational Site · Leeds, United Kingdom
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    3 sites added, 3 sites removed
    Show 3 added (1 Germany, 1 Netherlands, 1 United Kingdom)
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Rotterdam, Netherlands
    • GSK Investigational Site · Leeds, United Kingdom
    Show 3 removed
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Rotterdam, Netherlands
    • GSK Investigational Site · Leeds, United Kingdom
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05489237
Responsible party
Sponsor
First posted
Aug 5, 2022
Start date
Aug 3, 2022
Primary completion
Mar 10, 2027 (estimated)
Completion
Mar 26, 2027 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IDRX-42

Start the discussion